FOR IMMEDIATE RELEASE

Media Contact
Beth Mueller, (224) 948-5353
media@baxter.com

Investor Contact
Clare Trachtman, (224) 948-3085

BAXTER ANNOUNCES U.S. REGULATORY FILING FOR PRISMAX ACUTE CARE SYSTEM AND PRESENTATION OF 15 ABSTRACTS TO START ASN: KIDNEY WEEK 2018

- ***PrisMax*** *incorporates advanced technology for continuous renal replacement therapy (CRRT) designed to increase accuracy and performance for critically ill patients*
- *New data on HDx therapy and remote patient management (telehealth) to be presented*
- *Nephrologists will share perspectives on HDx and* ***Sharesource*** *at two ASN Spotlight sessions*

SAN DIEGO, OCTOBER 25, 2018 – Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced it has submitted the **PrisMax** system for 510(k) clearance to the U.S. Food and Drug Administration (FDA). Baxter intends to provide demonstrations of the **PrisMax** system at booth #1719 as well as present data on 15 abstracts on HDx therapy enabled by **Theranova** and **Sharesource** remote patient management innovations at the American Society of Nephrology's (ASN): Kidney Week 2018 meeting this week.

PrisMax is the company's most advanced technology for continuous renal replacement therapy (CRRT), which is performed when a patient experiences acute kidney injury. With input from more than 650 healthcare practitioners around the world, the acute care system was designed to make delivering therapy simpler and more efficient while improving treatment accuracy.

"We are thrilled to showcase our latest innovation for CRRT, along with our complete dialysis portfolio, at ASN: Kidney Week," said Gavin Campbell, general manager for Baxter's U.S. Renal

business. “This is another example of how Baxter is pioneering the latest advancements in dialysis, whether it’s for patients being treated in the hospital, clinic or home.”

Baxter also intends to highlight 13 data presentations on the safety, efficacy and health-related quality of life associated with HDx therapy, and two additional presentations on a reported reduction in hospitalizations and an increase in cost efficiencies for PD therapy associated with the use of remote patient management (telehealth) technology. Additionally, attendees can learn more about these therapies by attending featured spotlight sessions during the congress:

- “Remote Patient Management: **Sharesource** as a Driver of Change in Peritoneal Dialysis Therapy.” Attend the spotlight in-person on October 26th, or join via livestream.
- “Expanded Hemodialysis.” Join the speakers in-person on October 27th, or join the spotlight via livestream.

About Baxter

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

PrisMax is 510(k) pending and not currently available for sale in the United States.

*This release includes forward-looking statements concerning **PrisMax, Sharesource** and **Theranova**, including potential benefits associated with their use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 510-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.*

###